Owner Scorecard


← All companies ← LITB Manual LND → ← LGND Pharmaceuticals LLY →

LKFT, Lakefront Biotherapeutics

Pharmaceuticals consumer brand

We are a biotechnology company built to bring meaningful medicines to patients with serious diseases.

GLPG5101 and GLPG5301 are both cell therapy products, while GLPG3667 is a non-cell therapy product.

In both our oncology and I&I portfolios, we had multiple product candidates in early research stages as of December 2025.

Latest annual: FY2025 20-F · figures as filed, in EUR · 1 ADS = 1 ordinary share
LKFT · Lakefront Biotherapeutics
I

The business

What it sells, where the money comes from, the kind of company it is.

Revenue · FY2025
€1.1B
+303.5% YoY · 18% 5-yr CAGR
Vital signs · TTM, with 5-yr average
Revenue €1.1B 5-yr avg €421M
Operating margin 26.5% 5-yr avg −41.2%
ROIC 9% 5-yr avg −8%
Owner-earnings margin −24% 5-yr avg −149%
Free cash flow margin −24% 5-yr avg −156%

The business in brief

read the 10-K →

What this business is and what moves its needle, from its own SEC filings.

What moves the needle
Operating margin has reached 44% at its best but run negative through the cycle (median −37%) on a 97% gross margin — so the question is which reading is truer: whether the median was pulled below zero by one-off charges, by the cycle, or by spending it is still growing into, and whether it settles back at a profit. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.
Is it a good business?
Return on capital has rarely cleared the cost of capital (median −6%, above 15% in 0 of 6 years). Owner earnings, the cash-based check, have been thin too. This is price-taker territory, where the balance sheet and the cycle matter more than any multiple; the rest is in the 10-K.

Every line is arithmetic on the company's filings, shown in full in the sections below.

II

The record

Ten years of arithmetic, read across the cycle.

The record, 2016–2025

realized figures from each filing · older years to the left
2016’162017’172018’182019’192020’202021’212022’222023’232024’242025’25TTMTTMDec 2025
Income statement
€130M€127M€279M€835M€478M€234M€241M€240M€276M€1.1B€1.1BRevenueRevenue
99%87%97%97%Gross marginGross mgn
(€11M)(€90M)(€47M)€369M(€179M)(€172M)(€131M)(€88M)(€188M)€295M€295MOperating incomeOp. inc.
−8.9%−70.7%−16.9%44.2%−37.4%−73.2%−54.3%−36.8%−68.3%26.5%26.5%Operating marginOp. mgn
€54M(€116M)(€29M)€150M(€305M)(€103M)(€218M)€212M€74M€321M€321MNet incomeNet inc.
0%-0%4%-2%-6%-6%Effective tax rateTax rate
Cash flow & returns
€239M(€147M)(€142M)€3.2B(€427M)(€504M)(€501M)(€406M)(€320M)(€257M)(€257M)Operating cash flowOp. cash
€4M€4M€5M€12M€19M€31MDepreciationDeprec.
€181M(€36M)(€118M)€3.0B(€141M)(€401M)(€283M)(€618M)(€394M)(€578M)(€609M)Working capital & otherWC & other
€4M€5M€10M€22M€43M€54M€27M€19M€17M€14M€14MCapexCapex
3.4%4.2%3.7%2.7%8.9%23.1%11.4%7.8%6.1%1.2%1.2%Capex / revenueCapex/rev
€235M(€152M)(€148M)€3.2B(€446M)(€510M)(€507M)(€413M)(€328M)(€271M)(€271M)Owner earningsOwner earn.
181.4%−119.9%−52.9%382.8%−93.3%−217.7%−210.2%−172.1%−118.9%−24.4%−24.4%Owner earnings marginOE mgn
€235M(€152M)(€153M)€3.2B(€470M)(€558M)(€528M)(€425M)(€337M)(€271M)(€271M)Free cash flowFCF
181.4%−119.9%−54.9%381.6%−98.3%−238.1%−218.8%−177.2%−122.2%−24.4%−24.4%Free cash flow marginFCF mgn
-26%-33%-5%-3%-7%9%9%ROICROIC
7%-11%-2%5%-11%-4%-9%8%3%10%10%Return on equityROE
7%−11%−2%5%−11%−4%−9%8%3%10%10%Retained to equityRetained/eq
Balance sheet
€973M€1.2B€1.3B€5.8B€5.2B€4.7B€4.1B€3.7B€3.1B€3.0B€3.0BCash & investmentsCash+inv
€10M€28M€19M€54M€148M€111M€40M€28M€47M€21M€21MReceivablesReceiv.
€300K€279K€276K€255K€36K€21M€53M€74M€51M€22M€22MInventoryInvent.
€32M€48M€69M€143M€176M€138M€149M€135M€99M€105M€105MAccounts payablePayables
(€22M)(€20M)(€50M)(€89M)(€27M)(€6M)(€55M)(€33M)(€209K)(€61M)(€61M)Operating working capitalOper. WC
€1.0B€1.2B€1.3B€5.9B€5.4B€4.9B€4.2B€3.9B€3.3B€3.1B€3.1BCurrent assetsCur. assets
€104M€172M€220M€572M€635M€566M€523M€428M€335M€153M€153MCurrent liabilitiesCur. liab.
9.7×7.0×6.0×10.3×8.5×8.6×8.1×9.0×10.0×20.1×20.1×Current ratioCurr. ratio
€70M€70M€70M€70MGoodwillGoodwill
€1.1B€1.3B€1.4B€6.1B€5.7B€5.2B€4.7B€4.4B€4.1B€3.4B€3.4BTotal assetsAssets
(€973M)(€1.2B)(€1.3B)(€5.8B)(€5.2B)(€4.7B)(€4.1B)(€3.7B)(€3.1B)(€3.0B)(€3.0B)Net debt / (cash)Net debt
-244.5×-95.9×-60.4×290.8×-19.0×-14.8×-19.0×-49.9×-206.7×285.3×285.3×Interest coverageInt. cov.
€759M€1.0B€1.2B€2.9B€2.7B€2.6B€2.5B€2.8B€2.9B€3.2B€3.2BShareholders’ equityEquity
Per share
45.7M49.5M52.1M57.6M65.1M65.5M65.7M65.9M65.9M65.9M65.9MShares out (diluted)Shares
€2.83€2.57€5.35€14.49€7.35€3.58€3.67€3.64€4.18€16.88€16.88Revenue / shareRev/sh
€1.18€-2.34€-0.56€2.60€-4.69€-1.58€-3.32€3.21€1.12€4.87€4.87EPS (diluted)EPS
€5.14€-3.08€-2.83€55.48€-6.85€-7.79€-7.72€-6.26€-4.97€-4.11€-4.11Owner earnings / shareOE/sh
€5.14€-3.08€-2.93€55.30€-7.22€-8.52€-8.04€-6.45€-5.11€-4.11€-4.11Free cash flow / shareFCF/sh
€0.10€0.11€0.20€0.39€0.65€0.83€0.42€0.28€0.25€0.21€0.21Cap. spending / shareCapex/sh
€16.60€20.45€23.30€49.91€41.04€40.36€38.45€42.43€43.96€49.10€49.10Book value / shareBVPS
Per-share growththe realized rate an owner's share compounded
9-yr5-yr
Revenue / share+21.9%/yr+18.1%/yr
EPS+17.0%/yr
Capital spending / share+8.8%/yr−20.5%/yr
Book value / share+12.8%/yr+3.7%/yr

The record, charted

FY2016–2025

Each measure over its full record; the current point and the worst year marked.

Share count
66Mpeak FY2024
ROIC
9%low FY2021
Gross margin
97%low FY2024

Owner earnings vs. net income

Owner earningsNet income

The accountant's number, and the cash an owner can take; the gap is the tell.

(€271M)owner earningsvs.€321Mnet incomelow FY2021

Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.

In fiscal 2025 the business reported €321M of profit but (€271M) of owner earnings: €592M less than the profit line, taken out by capital spending and the timing of cash.

FY2025FY2024FY2023FY2022FY2021
Reported net income€321M€74M€212M(€218M)(€103M)
Working capital & othertiming of cash in and out, other non-cash items−€578M−€394M−€618M−€283M−€401M
Cash from operations(€257M)(€320M)(€406M)(€501M)(€504M)
Maintenance capital expenditurethe spending needed just to hold position and volume−€14M−€8M−€7M−€7M−€6M
Owner earnings(€271M)(€328M)(€413M)(€507M)(€510M)
Growth capital expenditurediscretionary; spent to get bigger, not to stand still−€9M−€12M−€21M−€48M
Free cash flow(€271M)(€337M)(€425M)(€528M)(€558M)
Owner-earnings marginowner earnings ÷ revenue-24%-119%-172%-210%-218%

Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position .

Much of fiscal 2025's profit didn't arrive as operating cash; it sits in “working capital & other” above. That can be a real inventory or timing swing, or profit that doesn't run through operating cash at all: a heavy tax year, equity-method earnings, or investment income booked through investing. For a year like this, owner earnings understates the cash earned; the full cash-flow statement carries the rest.

Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.

III

Quality & stewardship

Returns, the balance sheet, capital allocation, and pay.

Owner’s Scorecard

FY2025 20-F · source on SEC EDGAR →

Will it survive?

  • Comfortable
    Operating income €295M ÷ interest expense €1M
    What this means

    Operating profit covers interest with the kind of margin Graham wanted for a defensive holding. Necessary, not sufficient, it says solvent, not cheap.

  • Net cash, debt-free
    Cash €88M + ST investments €2.9B − debt €0
    What this means

    Cash and short-term investments exceed every dollar of debt by €3.0B, on net the company owes nothing, and can act from strength when others can't. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.

  • Negative, funded by others
    DSO 7 + DIO 276 − DPO 1285 days
    What this means

    Days cash is tied up between paying suppliers and collecting from customers. A negative cycle is a quiet moat: suppliers and customers fund the operation (Buffett's “float”), the company grows on other people's money.

Is it a good business?

  • Not enough data
    Industry peers: median -4%
    What this means

    The filing data didn't include the inputs for this check.

  • Consumes cash through the cycle
    10-yr median margin, range -218%–383%; latest (€271M) = operating cash (€257M) − maintenance capex €14M
    Industry peers: median -2%
    What this means

    What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's -24% of revenue this year, a -119% median across 10 years.

  • Thinly cash-backed
    Cash from ops (€257M) ÷ net income €321M

    In the filing’s words Read against the cash, reported earnings have run ahead of the operating cash the business generated over the record — about 6% of assets a year, among the widest gaps in the catalogue. For an inventory- or content-heavy grower that can be cash tied up in real assets as it expands; elsewhere it can mean the earnings lean on accounting estimates — the cash-flow statement against the income statement is where to tell which.

    What this means

    How much of reported profit showed up as operating cash. Above 1× is reassuring; well below suggests earnings lean on accruals. One year is noisy, growth and working-capital swings distort it, and this is operating cash, not free cash. Watch the multi-year trend.

How is the cash used?

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

  • Investing or harvesting? 0.45×
    Harvesting
    Capex €14M ÷ depreciation €31M
    What this means

    Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.

Graham’s defensive tests · 1 of 3 met

Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.

  • Adequate size
    Revenue ≥ $2B (a dollar floor) · €1.1B
    What this means

    Big enough to weather a storm. Graham's floor is a dollar figure — about $2B of revenue as a conservative modern stand-in. This company reports in its home currency and we carry no exchange rate, so we show the figure and leave the size bar for you to apply rather than convert it with a number we don't have.

  • Strong liquidity Pass
    Current ratio ≥ 2× · 20.15×
    What this means

    Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.

  • Earnings stability Miss
    A profit every year (10-yr record) · 5 loss years
    What this means

    Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.

  • Dividend record Miss
    Uninterrupted dividends · none paid
    What this means

    An unbroken dividend was Graham's mark of durability. He wanted twenty years; the filings show about ten, and a single suspension breaks the streak. Non-payers, many fine modern compounders, fall outside his defensive net by design.

  • Earnings growth
    Earnings +33% over the record ·
    What this means

    Earnings were negative early in the record, a growth rate isn't meaningful.

  • Moderate price
    P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
    What this means

    Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are €3.07/share (latest year €4.87), the averaged base the calculator's gate runs on, and book value is €49.10/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.

Durability & moat, 2016–2025

Whether the record’s returns held, and what the capital reinvested earned.

  • Profitable years 5 of 10
    What this means

    Lost money in 5 year(s), look at what happened there before trusting the average.

  • Operating margin −32% → −26% (3-yr avg ends)

    In the filing’s words Input costs rose and the filing says it recovered them in price — consistent with the margin holding here.

    What this means

    Through the cycle the operating margin widened — about −32% early to −26% lately, median −37% — pricing power intact or improving.

  • Worst year 2021 · −73.2% op. margin
    What this means

    Operations went underwater in 2021, understand why before trusting the good years.

  • Share count +4.2%/yr
    What this means

    The share count is rising, dilution works against you on a per-share basis.

  • How management talks about it Promotional
    What this means

    The record is compounding, but the filing leans on a promoter’s vocabulary rather than the per-share, return-on-capital terms an owner uses. The results back the talk here; the register is still worth noting.

Does AI threaten the moat?

Low contestability

The moat is physical, regulated or balance-sheet-funded, the kind AI cuts costs within but does not contest.

In its own filing Framed as a capability

The filing positions AI as something the company uses, not something it fears.

“Equity investment in Frontier Medicines On January 31, 2024, we participated for $40.0 million in the Series C financing round of Frontier Medicines, a pioneer in oncology with a unique FrontierTM platform based on chemoproteomics, covalent chemistry and machine learning to unloc…”

AI is unlikely to contest a moat that is physical, regulated or balance-sheet-funded; here it reads more as a cost tool than a threat, and the company is using it that way.

Read from the filing's own risk factors, paired with the industry's structure under its SIC code; the durability is read above, the price below.

All figures as filed; the source filing is linked above.

Current Position

as of fiscal year-end, Dec 31, 2025

Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.

Current assets€3.1B
  • Cash & short-term investments€3.0B
  • Receivables€21M
  • Inventory€22M
  • Other current assets€38M
Current liabilities€153M
  • Accounts payable€105M
  • Other current liabilities€48M
Current ratio20.15×all current assets ÷ what's due · Graham looked for 2×
Quick ratio20.00×stricter: inventory excluded
Cash ratio19.61×strictest: cash alone against what's due
Working capital€2.9Bthe cushion left after near-term bills
Cash runway11.1 yrsthe business is consuming cash; this is how long the cash on hand lasts at that rate
Deeper floors
Tangible book value€3.2Bequity stripped of goodwill & intangibles
Net current asset value€2.9BGraham's net-net: current assets less all liabilities
Debt incl. operating leases€7M€7M of it operating leases

From the company's latest filing.

How the cash was used, 2016–2025

Over the record, the business generated €743M of operating cash; how management split it reads as a cash builder, a large share of cash simply built up on the balance sheet.

  • Reinvested€216M · 29%
  • Retained (debt / cash)€528M · 71%
  • Source of fundingOperating cash

    Operating cash covered reinvestment and returns; over the span cash and short-term investments rose €2.0B.

  • Net change in share count44.2%

    The diluted count rose from 46M to 66M: issuance (stock pay, deals) outran any buybacks, so owners were diluted on net.

  • Dividend record

    No dividend line was reported in the filing data over the span; the record here neither confirms nor rules out a payout.

  • Return on what it retained−811%

    Of the earnings it kept rather than paid out (€39M over the span), annual owner earnings (first three years vs last three) fell €315M, so each retained €1 gave back about 8.11 of yearly owner earnings. Buffett's test, run on owner earnings instead of market value.

Buybacks are gross of stock issued to staff; the share-count line above is the net of that, the figure that decides whether owners gained. The average price paid blends a year of purchases (and any accelerated repurchase), so it is close, not exact. The record of where the cash went and on what terms.

Inverting the record

Invert: instead of why Lakefront Biotherapeutics is a good business, the question is what would make owning it a mistake, and whether those marks are in the record. Disconfirming tests across 2016–2025.

1 of the 4 tests turned up something to look into; the other 3 came back clean.

  • Look hereDid the share count rise anyway?44.2%

    Diluted shares grew 44.2% over 2016–2025. Owners were diluted on net; each share owns less of the business than it did. Read the buyback line beside this one, not on its own.

And these came back clean
  • Is it less profitable than it was?
  • Did reported profit become cash?
  • Did receivables and inventory outpace sales?

Each test is read from the filings and is noisy alone; a flag can mark a cyclical trough or a year of heavy investment as easily as a problem. The filing says which.

Peers, Pharmaceuticals

The same industry, side by side on owner economics. Each figure is a through-cycle median, so a peak or trough year can’t distort it; the group median at the foot is the line to read each against.

CompanyRevenueGross marginOp. marginROICOwner earn. margin
PAHCPhibro Animal Health Corporation$1.3B32%8.8%16%3%
INDVIndivior Pharmaceuticals Inc.$1.2B82%-2.9%-2%
LKFTLakefront Biotherapeutics€1.1B97%-37.1%-6%-106%
PBHPrestige Consumer Healthcare$1.1B56%29.0%8%21%
ACADACADIA Pharmaceuticals Inc.$1.1B94%-54.1%-48%-29%
MDGLMadrigal Pharmaceuticals Inc.$958M99%-276.4%-61%-254%
IONSIonis Pharmaceuticals$944M99%-16.9%-11%-14%
ANIPANI Pharmaceuticals Inc.$883M62%8.8%4%17%
Group median88%-9.9%-6%-8%
IV

The price

What a price has to assume.

What the price implies

reverse-DCF

Enter the US price, in dollars: the NYSE/Nasdaq quote you hold. Per the filing's own cover, “American Depositary Shares, each representing one ordinary”; Lakefront Biotherapeutics reports in EUR, so every figure in this tool is stated per ADS and translated at EUR 1 = $1.145 (2026-07-17, reference rate) so your dollar quote reconciles exactly. The record tables elsewhere on this page remain as filed, in EUR.

Lakefront Biotherapeutics is profitable, but owner earnings are negative this year because capital spending currently outruns operating cash, a build-out, so the owner-earnings reverse-DCF has no positive base to grow. We read the price from both ends instead: type a price to see the steady-state profitability it demands, then set the mature margin you would believe and weigh the two against each other. Nothing leaves your browser unless you enter it in your notebook.

$
The assumptions

Revenue, delivered14%/yr’20→’25

Enter a price to run it.

Owner earnings it must reach
Margin the price demands
Owner-earnings margin today−24%

Two reads of one future. From your price: the owner earnings the company must reach, valued at a mature multiple and discounted back at your rate, expressed as the margin it implies on revenue grown at your rate. From your belief: the mature margin you would credit, set on the dial above. When the margin the price demands runs above the one you would believe, you are paying for a future taken on faith. For a deep cyclical at a trough, normalized through-cycle earnings are the better lens; this mode is for the genuinely unprofitable, and for the profitable business whose capital spending currently outruns its cash.

Cite: Owner Scorecard, "Lakefront Biotherapeutics (LKFT), the owner's record," https://ownerscorecard.com/c/LKFT, data as of 2026-07-09.

Manual order: ← LITB its page in the Manual LND →

Industry order: ← LGND the Pharmaceuticals chapter LLY →